<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 S621 IS: Safe Prescribing Act of 2013</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2013-03-20</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 621</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130320">March 20, 2013</action-date>
			<action-desc><sponsor name-id="S338">Mr. Manchin</sponsor> (for
			 himself, <cosponsor name-id="S339">Mr. Kirk</cosponsor>,
			 <cosponsor name-id="S221">Mrs. Feinstein</cosponsor>, <cosponsor name-id="S176">Mr. Rockefeller</cosponsor>, <cosponsor name-id="S331">Mrs.
			 Gillibrand</cosponsor>, and <cosponsor name-id="S270">Mr. Schumer</cosponsor>)
			 introduced the following bill; which was read twice and referred to the
			 <committee-name committee-id="SSJU00">Committee on the
			 Judiciary</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Controlled Substances Act to make any
		  substance containing hydrocodone a schedule II drug.</official-title>
	</form>
	<legis-body>
		<section id="idF3AAD1A617BC44EF96B776D1088C2F14" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote><short-title>Safe Prescribing Act of
			 2013</short-title></quote>.</text>
		</section><section id="idB49043BCCF384A1483A6EEB89A0CB81B" section-type="subsequent-section"><enum>2.</enum><header>Hydrocodone
			 amendment</header>
			<subsection id="id0F0C5ED9702E4289BF00B4ABF691866B"><enum>(a)</enum><header>In
			 general</header><text display-inline="yes-display-inline">Schedule III(d) in
			 section 202 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812</external-xref>) is amended
			 by—</text>
				<paragraph id="idDA316AFF8843449E9CF3FAF0D8CE1A0B"><enum>(1)</enum><text display-inline="yes-display-inline">striking paragraphs (3) and (4); and</text>
				</paragraph><paragraph id="idDD09F572A1824C729AA174A9909DDB23"><enum>(2)</enum><text display-inline="yes-display-inline">redesignating paragraphs (5), (6), (7), and
			 (8) as paragraphs (3), (4), (5), and (6), respectively.</text>
				</paragraph></subsection><subsection id="id4E7EBC62782946169CD275E9D8D99261"><enum>(b)</enum><header>Effective
			 date</header><text>The amendments made by subsection (a) shall take effect on
			 the date that is 6 months after the date of enactment of this Act.</text>
			</subsection></section><section id="id5C2CDBAACC034FFF9C933C1BFF49B11E"><enum>3.</enum><header>Physical
			 security requirements</header><text display-inline="no-display-inline">Notwithstanding the amendments made by
			 section 2, the Attorney General shall immediately, without regard to chapter 5
			 of title 5, United States Code, amend <external-xref legal-doc="usc" parsable-cite="usc/21/1301">section 1301.72</external-xref> of title 21, Code of
			 Federal Regulations, relating to the physical security controls for
			 non-practitioners, narcotic treatment programs and compounders for narcotic
			 treatment programs, and storage areas for controlled substances, to allow, for
			 the 3-year period beginning on the date of enactment of this Act, manufacturers
			 and distributors to store hydrocodone combination products in accordance with
			 the physical security requirements for schedule III, IV, and V controlled
			 substances.</text>
		</section><section id="idC36B04F5396A44CB92EADCD629036C75"><enum>4.</enum><header>GAO
			 report</header>
			<subsection id="id0E4EB6C7D1424A3783F7ECEF2B3960AE"><enum>(a)</enum><header>In
			 general</header><text display-inline="yes-display-inline">Not later than 18
			 months after the date of enactment of this Act, the Comptroller General of the
			 United States shall submit to Congress a report on the reclassification of
			 hydrocodone products under this Act.</text>
			</subsection><subsection id="id5EC90FD500E444B38C314B540D9C3E40"><enum>(b)</enum><header>Contents</header><text>The
			 report required under subsection (a) shall include—</text>
				<paragraph id="idF994C2C8020D444FB4754CB52B802084"><enum>(1)</enum><text>an assessment of
			 the degree to which the reclassification of hydrocodone products under this Act
			 impacts the ability of patients with legitimate medical needs, particularly
			 those in rural areas and nursing home facilities, to access adequate pain
			 management; and</text>
				</paragraph><paragraph id="idBC7B44F522184CB79D834C387C96342F"><enum>(2)</enum><text>recommendations
			 necessary to address issues, if any, relating to patient access to adequate
			 pain management.</text>
				</paragraph></subsection></section></legis-body>
</bill>


